Literature DB >> 6085051

Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.

T Zetterström, T Sharp, U Ungerstedt.   

Abstract

This study investigated the effect of three neuroleptic drugs, (+/-)-sulpiride, haloperidol and cis-flupenthixol, on dopamine release and metabolism in the striatum of the awake rat. Endogenous extracellular dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as the 5-hydroxytryptamine (5HT) metabolite 5-hydroxyindoleacetic acid (5HIAA), were determined in striatal perfusates in awake rats by using intracerebral dialysis together with high performance liquid chromatography with electrochemical detection. Sulpiride (10, 50 and 250 mg/kg), cis-flupenthixol (0.5 and 2 mg/kg) and haloperidol (2 mg/kg) all increased the levels of dopamine in striatal perfusates. However, the time course and magnitude of these effects differed markedly depending upon the neuroleptic used. Sulpiride (10, 50 and 250 mg/kg), cis-flupenthixol (0.05, 0.5 and 2 mg/kg) and haloperidol (0.05, 0.5 and 2 mg/kg) increased extracellular levels of DOPAC and HVA while having little effect on 5HIAA. In contrast to the effect on dopamine levels the changes in DOPAC and HVA followed similar time courses and were of similar magnitude independent of the neuroleptic used. The response of the dopamine metabolites seemed to occur at lower doses of the neuroleptics than the response of dopamine release itself. Furthermore, there was no close relationship between changes in dopamine as compared to changes in DOPAC and HVA. Finally, there was no correlation between any of the neurochemical changes measured and the occurrence of catalepsy. These data suggest that neuroleptic drugs have two separate actions on the dopamine neuron in vivo, one causing an increase in dopamine release and another producing an increase in dopamine metabolism, which is probably a consequence of increased dopamine synthesis. Furthermore neither of these effects are related to catalepsy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6085051     DOI: 10.1016/0014-2999(84)90674-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  37 in total

1.  Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol.

Authors:  William S Cobb; Elizabeth D Abercrombie
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

2.  Regulatory aspects of nigrostriatal dopaminergic neurons.

Authors:  P Miu; F Karoum; G Toffano; J W Commissiong
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

3.  Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Authors:  F P Bymaster; S K Hemrick-Luecke; K W Perry; R W Fuller
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2006-08-30       Impact factor: 4.530

Review 5.  Do autoreceptors mediate dopamine agonist--induced yawning and suppression of exploration? A critical review.

Authors:  L Ståhle
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine.

Authors:  B A Bailey; S R Philips; A A Boulton
Journal:  Neurochem Res       Date:  1987-02       Impact factor: 3.996

7.  Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

Authors:  C A Altar; W C Boyar; A Wasley; S C Gerhardt; J M Liebman; P L Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

Review 8.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Tyrosine hydroxylase-negative, dopaminergic neurons are targets for transmitter-depleting action of haloperidol in the snail brain.

Authors:  D A Sakharov; E E Voronezhskaya; L Nezlin; M W Baker; K Elekes; R P Croll
Journal:  Cell Mol Neurobiol       Date:  1996-08       Impact factor: 5.046

10.  Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.

Authors:  F Duval; M C Mokrani; J P Macher; M A Crocq; J O Castro; P Bailey; X Lataste
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.